Business Context and Reporting Period
This summary covers the Form 10-Q for Salarius Pharmaceuticals, Inc. (SLRX) for the quarterly period ended June 30, 2025. Although the request metadata referenced Decoy Therapeutics, the filing text identifies Salarius as the registrant. Salarius is a clinical-stage biopharmaceutical company focused on cancer treatments (SP-3164 and seclidemstat) with no approved products or product revenue. The company is currently in a critical phase regarding its ability to continue as a going concern, pending the completion of a proposed merger with Decoy Therapeutics Inc. and the securing of a "Qualified Financing" of at least $6.0 million.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(957,825) | $(2,667,358) | $(3,139,723) |
| Loss Per Share (Basic/Diluted) | $(0.45) | $(1.41) | $(5.62) |
| Cash and Cash Equivalents (End of Period) | $794,886 | $794,886 | $3,272,823 |
| Working Capital | $(862,924) | $(862,924) | N/A |
| Stockholders' Equity (Deficit) | $(829,724) | $(829,724) | $2,375,353 |
| Net Cash Used in Operating Activities | N/A | $(2,044,011) | $(2,426,147) |
| Net Cash Provided by Financing Activities | N/A | $404,369 | $(200,940) |
Note: The filing states that as of the report date (August 2025), cash balances are approximately $3.4 million and stockholders' equity is above $2.5 million due to subsequent financing activities.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 34% year-over-year for the six months ended June 30, 2025 ($2.68M vs. $3.24M). This was driven by a cost-savings plan implemented in late 2023, resulting in reduced personnel costs and curtailed sponsored clinical trials.
- Liquidity Deterioration: Cash and cash equivalents dropped from $2.43 million at year-end 2024 to $0.79 million at June 30, 2025. Consequently, the company moved from positive stockholders' equity ($1.51M) to a deficit of $(0.83M).
- Financing Activity: The company raised approximately $0.63 million net from equity issuances (ATM and ELOC) during the six months ended June 30, 2025, compared to $0.09 million in the prior year period.
Outlook, Risks, and Management Commentary
Merger with Decoy Therapeutics
Salarius is pursuing a merger with Decoy Therapeutics Inc. The transaction is contingent upon a "Qualified Financing" of at least $6.0 million and maintaining Nasdaq listing. Recent amendments to the Merger Agreement (Amendments 1-4) have adjusted the exchange ratio due to Salarius's declining stock price, reducing legacy Salarius stockholder ownership in the combined entity to approximately 7.6% (pre-financing). The merger also involves the conversion of Decoy's promissory notes into Series B Preferred Stock.
Liquidity and Going Concern
Management has raised substantial doubt about the company's ability to continue as a going concern. As of June 30, 2025, cash was insufficient to fund operations beyond the second quarter of 2026. However, subsequent to the period end (July 2025), the company sold shares under its ELOC agreement for approximately $3.8 million, which management believes extends the cash runway into Q2 2026. If the merger fails to close and additional capital cannot be raised, the company may be forced to liquidate.
Nasdaq Compliance Risks
Salarius received notice of non-compliance with Nasdaq listing rules regarding the Minimum Bid Price ($1.00) and Stockholders' Equity ($2.5 million). The company appealed the delisting determination and received an extension from the Nasdaq Hearings Panel to regain compliance by late August 2025. Failure to meet these milestones could result in delisting.
Operational Strategy
The company has significantly reduced its workforce to two full-time employees and consultants. It has paused sponsored clinical trials, intending to rely on data from an investigator-initiated trial at MD Anderson Cancer Center before deciding on future development steps.
Investor Verification Checklist
- Merger Closing Conditions: Verify if the $6.0 million "Qualified Financing" has been successfully consummated and if the merger with Decoy Therapeutics has closed.
- Nasdaq Status: Confirm whether Salarius has regained compliance with Nasdaq listing standards (Minimum Bid Price and Equity Standard) by the August 2025 deadline to avoid delisting.
- Subsequent Financing: Validate the $3.8 million in proceeds from the ELOC agreement mentioned in subsequent events and confirm the current cash balance.
- Dilution Impact: Review the final ownership structure post-merger, noting the reduction of legacy Salarius stockholder ownership to ~7.6% and the terms of the new Series A and Series B Preferred Stock.
- Liquidation Risk: Assess the likelihood of the company winding down operations if the merger is terminated or financing fails.